PI(4)K Inhibitor Could Prove Cure For Killer Diarrhoea
Cryptosporidium parvum. Credit: EPA/H.D.A. Lindquist
Infectious disease scientists from Novartis, the University of Georgia and Washington State University have reported the discovery and early validation of a drug candidate for treating cryptosporidiosis, a diarrheal disease which is a major cause of child mortality in lower-income countries. Currently there are no vaccines or effective treatments.
"There's a lot of uncertainty when embarking on drug discovery for a notoriously intractable parasite such as Cryptosporidium, the cause of cryptosporidiosis," said Thierry Diagana, Head of the Novartis Institute for Tropical Diseases (NITD). "Thanks to the commitment of our funding collaborators and urgent action of our academic colleagues, we've made an important step toward advancing a new treatment."
Diarrheal diseases cause more than 800,000 deaths annually1. Epidemiological studies have highlighted the vital need for new treatment options against the protozoan parasite Cryptosporidium, which often infects its victims from exposure to contaminated water supplies. Nitazoxanide, the only approved treatment for cryptosporidiosis, has shown poor results in vulnerable infants and immune-compromised patients2,3.
Yet there are obstacles to finding new treatments. The parasite perishes relatively quickly in labs and scientists have lacked research tools to identify drug candidates. The team developed a novel drug discovery process using transgenic parasites and novel disease models, leading to the identification and validation of the Cryptosporidium PI(4)K inhibitor candidate KDU731. They reported the discovery and preclinical findings in a recent issue of Nature4.
Novartis is advancing research of cryptosporidiosis through collaborations with the global health community and its scientists at NITD, which is ramping up its research and operations in Emeryville, CA.
1. Liu, L. et al. Global, regional, and national causes of under-5 mortality in 2000-15: an updated systematic analysis with implications for the Sustainable Development Goals. The Lancet. 2016.
2. Amadi, B. et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC infectious diseases. 2009.
3. Amadi, B. et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. The Lancet. 2002
4. Manjunatha, U., Vinayak, S., Zambriski, J., Chao, A., Sy, T., Noble, C., Bonamy, G., Kondreddi, R., Zou, B., Gedeck, P., Brooks, C., Herbert, G., Sateriale, A., Tandel, J., Noh, S., Lakshminarayana, S., Lim, S., Goodman, L., Bodenreider, C., Feng, G., Zhang, L., Blasco, F., Wagner, J., Leong, F., Striepen, B. and Diagana, T. (2017). A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature.
This article has been republished from materials provided by Novartis. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Fancy A Jellyfish Chip?News
Mineral-rich jellyfish have been a staple in Asian cuisine for centuries, but remain an oddity to the western palate. Traditionally, they are marinated in salt and potassium alum for several weeks to produce a crunchy, pickle-like texture. Research have now developed a new technique that produces the same results in only a few days.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018